Начало・Списък с акции・ImmunityBio Inc

ImmunityBio Inc

Затворен

СекторЗдравеопазване

7.53 -1.31

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.51

Максимум

7.64

Ключови измерители
By Trading Economics
Приходи	-571M -633M
Продажби	5.9M 44M
EPS	-0.08
Марж на печалбата	-1,431.439
Служители	684
EBITDA	-569M -600M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+70.16% upside

Дивиденти
By Acuity
Следващи печалби	2.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-293M 7.5B
Предишно отваряне	8.84
Предишно затваряне	7.53

Настроения в новините

By Acuity

50%

128 / 340 Класиране в Healthcare

ImmunityBio Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.08.2026 г., 23:06 ч. UTC

Immunitybio Inc's shares are lower in after-market hours, with no specific news driving the decline. The stock remains above its 20-day moving average.

6.08.2026 г., 23:11 ч. UTC

Immunitybio Inc's shares are higher in after-market trading, reflecting a slight increase since Thursday's close, though still below the 20-day moving average.

5.08.2026 г., 19:26 ч. UTC

Immunitybio Inc's shares are higher today amid positive market sentiment. The stock is recovering from earlier weakness despite remaining below its 20-day moving average.

4.08.2026 г., 23:46 ч. UTC

Immunitybio Inc. shares are trading roughly flat in after-market hours. The asset remains significantly below its 20-day moving average.

3.08.2026 г., 23:21 ч. UTC

Immunitybio Inc shares rose in after-market trading, settling higher since Monday's close. The stock remains below its 20-day moving average.

1.08.2026 г., 00:02 ч. UTC

Immunitybio Inc shares are higher in after-market trading, reflecting a notable increase since Friday's close amid broader market dynamics.

31.07.2026 г., 23:06 ч. UTC

Immunitybio Inc's shares are higher in after-market trading, though no specific news was identified to explain the movement. The stock remains below its 20-day moving average.

30.07.2026 г., 19:29 ч. UTC

Immunitybio Inc is trading higher, recovering from an earlier drop. The stock has rebounded significantly since Wednesday's close, despite six consecutive lower daily closes.

29.07.2026 г., 23:41 ч. UTC

News

ImmunityBio receives UAE marketing authorization for ANKTIVA®, expanding its reach to 34 countries. Shares are trading higher in after-market hours following the announcement.

28.07.2026 г., 20:06 ч. UTC

News

ImmunityBio Inc is under investigation for potential wrongdoing, contributing to its decline today. Shares remain lower since Monday's close, marking six consecutive sessions of losses.

27.07.2026 г., 19:16 ч. UTC

Immunitybio Inc. shares are lower, continuing a four-session decline amid broader market pressures and a significant drop in oil prices.

24.07.2026 г., 23:06 ч. UTC

Immunitybio Inc shares are higher in after-market hours following Friday's close, settling with a cumulative increase after earlier gains. No specific news was identified.

23.07.2026 г., 09:16 ч. UTC

Immunitybio Inc shares are higher in pre-market hours, continuing an upward trend since Wednesday. This movement occurs amid broader market pressures from disappointing tech earnings.

22.07.2026 г., 19:11 ч. UTC

Immunitybio Inc's shares are lower today, diverging from recent gains. The stock is seeing unusually high trading volume amid rising crude oil prices.

21.07.2026 г., 18:06 ч. UTC

Immunitybio Inc is trading higher during Tuesday's session amid positive market sentiment. No specific company news was identified to explain the movement.

20.07.2026 г., 23:46 ч. UTC

Immunitybio Inc. shares are higher in after-market trading, reflecting routine activity. The stock remains below its 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

ImmunityBio Inc Прогноза

Ценова цел

By TipRanks

70.16% нагоре

12-месечна прогноза

Среден 13 USD 70.16%

Висок 15 USD

Нисък 12 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за ImmunityBio Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на ImmunityBio Inc през последните 3 месеца.

Настроение

By Acuity

128 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.